enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves new COPD drug developed by firm in Raleigh ... - AOL

   www.aol.com/news/fda-approves-copd-drug...

   A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.

3. Global Initiative for Chronic Obstructive Lung Disease

   en.wikipedia.org/wiki/Global_Initiative_for...

   [1] [2] They have organized the annual awareness day, World COPD Day, every November since 2002. [3] This organization issues recommendations for the treatment of chronic obstructive pulmonary disease and related medical conditions. GOLD issued its first formal recommendations in 2001. [2]

4. First new asthma attack treatment in 50 years - AOL

   www.aol.com/news/first-asthma-attack-treatment...

   The study, on 158 people, monitored patients for three months after treatment for a flare-up. The results in The Lancet Respiratory Medicine found a treatment failure rate of: 74% when taking steroids

5. The Most Exciting New Advances in Managing COPD - AOL

   www.aol.com/most-exciting-advances-managing-copd...

   For people with COPD—and their care providers—the future looks bright. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail ...

6. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

7. Benralizumab - Wikipedia

   en.wikipedia.org/wiki/Benralizumab

   In November 2024, the ABRA study found that a single dose of benralizumab could be more effective when injected at the point of exacerbation compared to currently used steroid tablets in patients at high risk of an asthma or chronic obstructive pulmonary disease (COPD). [10] [11]